Andere talen UroGen Pharma Ltd.

Aandelen

URGN

IL0011407140

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
16,49 ^USD	-5,61%		-2,25%	+9,93%

14/06	UROGEN PHARMA LTD. : Oppenheimer herhaalt koopadvies voor het aandeel	ZM
14/06	UROGEN PHARMA LTD. : Ladenburg Thalmann herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials	18/06
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants	18/06
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants	17/06
Sector Update: Health Care Stocks Ease Late Afternoon	13/06
Sector Update: Health Care Stocks Softer Thursday Afternoon	13/06
Top Midday Gainers	13/06
UroGen Pharma Shares Surge After 'Unprecedented' Results on Bladder Cancer Therapy Trial	13/06
UroGen Pharma Ltd. Announces Positive Secondary Endpoint Duration of Response (?Dor?) Data from the Phase 3 ENVISION	13/06
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC	13/06
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/06
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024	06/06
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference	05/06
UroGen Pharma Appoints David Lin as New Chief Commercial Officer	03/06
UroGen Pharma Appoints David Lin as New Chief Commercial Officer	03/06
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit	22/05
Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M	13/05
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights	13/05
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07/05
UroGen Pharma to Participate at Upcoming Investor Conferences	07/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen UroGen Pharma Ltd.

Aandelen

URGN

IL0011407140

Andere talen

Filters